

Benefits of surgeon-controlled fluoroscopy outweigh concerns

Todd S. Yecies, MD; Timothy D. Averch, MD

Department of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA, United States

Cite as: *Can Urol Assoc J* 2016;10(11-12):403-4. <http://dx.doi.org/10.5489/cuaj.4248>

See related article on page 398.

In the study by Setterfield et al, the authors performed a retrospective analysis of patients undergoing fluoroscopy-guided endourological procedures, excluding percutaneous nephrolithotomy, with fluoroscopy being controlled by either a radiation technologist (RT) or the operating surgeon.¹ They found that surgeon control of fluoroscopy did not lead to reduced fluoroscopy times and, in fact, was associated with increased fluoroscopy time during ureteroscopy (URS) with laser lithotripsy, although this difference was not found to be significant on multivariate analysis. We agree with the authors' premise that reducing patient and surgeon radiation exposure to "as low as reasonably achievable" (ALARA) levels is of paramount importance, and applaud their goals in designing a study to look at this potentially modifiable factor.

While there is no direct evidence demonstrating that patient radiation exposure during endourological procedures is associated with adverse effects, such as risk of secondary malignancy, the literature in other medical fields gives significant cause for alarm. In a study of patients who underwent cardiac imaging after myocardial infarction, five-year risk of malignancy was found to increase by 3% for every 10 mSv of radiation exposure.² Ferrandino et al demonstrated a median radiation dose of 29.7 mSv over a one-year period in patients with an acute stone episode,³ and many patients with nephrolithiasis have multiple stone episodes. As such, any and all approaches to reducing patient radiation exposure should be considered.

While the authors did not show any reduction in fluoroscopy time with surgeon control, this should be interpreted in light of the study's limitations. The study was retrospective in design and the nature of the intervention being studied precludes blinding, which carries risk of observation bias. It is also difficult to explain why the authors found that RT control of fluoroscopy reduced fluoroscopy time during URS with laser lithotripsy, but had the opposite effect dur-

ing diagnostic URS. After adjusting for case-based factors that may be markers of more difficult procedures, such as access sheath and guidewire usage, these results were not significant. This suggests that the variation in fluoroscopy time observed during this study was based more on intraoperative factors than on the use of RT- or surgeon-controlled fluoroscopy. Additionally, during the time period in which surgeons controlled fluoroscopy, degree of resident control of fluoroscopy was unknown, which could affect fluoroscopy times. As the authors note, a randomized, controlled trial of surgeon- vs. RT-controlled fluoroscopy is currently accruing at Boston Children's Hospital, which may help address these questions.

It is important to note that while radiation exposure is an important consideration when deciding whether the surgeon or RT should control fluoroscopy, many other factors must be considered. Direct surgeon control can allow for more precise timing of fluoroscopy during delicate portions of the procedure, such as when attempting to pass an impacted stone or stricture with a wire. Another concern is that a single surgeon is likely to work with multiple RTs of varying degrees of experience and skill. While the effect of RT experience during URS has not been studied, Elkoushy et al found that during extracorporeal shock wave lithotripsy (ESWL), different RTs had highly variable fluoroscopy times and stone clearance rates that correlated with RT experience.⁴ Surgeon control of fluoroscopy removes RT experience as a source of concern. Finally, many urologists practice using operating tables with built-in C-arms or in settings where dedicated fluoroscopy RTs may not be available; becoming facile with surgeon-controlled fluoroscopy is an important skill. Conversely, the need to manipulate a fluoroscopy pedal could distract the surgeon's attention from other aspects of the procedure, although this can be partially mitigated by strategically positioning the fluoroscopy pedal in a convenient location at the beginning of the procedure.

At our institution, we feel that the benefits of surgeon control of fluoroscopy outweigh the concerns; however, we acknowledge that this will depend on the comfort level of the individual surgeon.

Competing interests: Dr. Yecies reports no competing personal or financial interests. Dr. Averch was a speaker for Bard Medical.

References

1. Setterfield J, Watterson J, Mathew Playfair M, et al. Should surgeons control fluoroscopy during urology procedures? *Can Urol Assoc J* 2016;10(11-12):398-402. <http://dx.doi.org/10.5489/cuoj.3895>
2. Eisenberg MJ, Afilalo J, Lawler PR, et al. Cancer risk related to low-dose ionizing radiation from cardiac imaging in patients after acute myocardial infarction. *CMAJ* 2011;183:430-6. <http://dx.doi.org/10.1503/cmaj.100463>

3. Ferrandino MN, Bagrodia A, Pierre SA, et al. Radiation exposure in the acute and short-term management of urolithiasis at 2 academic centres. *J Urol* 2009;181:668-72. <http://dx.doi.org/10.1016/j.juro.2008.10.012>
4. Elkoushy MA, Morehouse DD, Anidjar M, et al. Impact of radiological technologists on the outcome of shock wave lithotripsy. *Urology* 2012;79:777-80. <http://dx.doi.org/10.1016/j.urology.2011.09.013>

Correspondence: Dr. Timothy Averch, Department of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA, United States; averchtd@upmc.edu



Indications and clinical use:

²²³Xofigo® (radium Ra 223 dichloride) is indicated for the treatment of patients with castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastatic disease.

This product should be administered under the supervision of a qualified health professional who is experienced in the use of therapeutic radiopharmaceuticals.

Geriatrics (>65 years of age): No dosage adjustment is considered necessary in elderly patients. Although no overall differences in safety or efficacy were observed between elderly (aged ≥65 years) and younger patients (aged <65 years), the potential for greater sensitivity of some older individuals cannot be ruled out.

Contraindications:

Xofigo® is contraindicated in pregnancy. Xofigo® can cause fetal harm when administered to a pregnant woman based on its mechanism of action. Xofigo® is not indicated for use in women.

Most serious warnings and precautions:

Use of Radiopharmaceuticals: Should be used only by those health professionals who are appropriately qualified in the use of radioactive-prescribed substances in or on humans.

Bone Marrow Suppression: Measure blood counts prior to treatment initiation and before every dose.

Other relevant warnings and precautions:

- Xofigo® should be received, stored, used, transferred, administered and disposed of by authorized persons.
- Spinal Cord Compression: In patients with untreated, imminent or established spinal cord compression (SCC), treatment for SCC should be completed before starting or resuming treatment with Xofigo®.
- Bone Fractures: In patients with bone fractures, stabilization of fractures should be performed before starting or resuming Xofigo®.

- Contamination: Caregivers should take precautions to avoid risk of contamination. This includes:
 - wearing gloves and hand-washing when handling bodily fluids
 - promptly cleaning clothing – separately – that has been soiled with Xofigo®, patient fecal matter or urine
 - having the patient use a toilet and flush the toilet twice after use
- Gastrointestinal: Patients with inflammatory bowel disease and increased risk of bowel obstruction should be treated with caution. Appropriate monitoring and consideration of additional supportive measures may be required in patients with constipation. Safety and efficacy in patients with Crohn's disease or ulcerative colitis have not been determined.
- Bone Marrow Suppression: Bone marrow suppression has been reported in patients treated with Xofigo®; therefore, hematological evaluation of patients must be performed at baseline and prior to every dose of Xofigo®. Patients with evidence of compromised bone marrow reserve should be monitored closely and provided with supportive care. Xofigo® should be discontinued in patients who experience life-threatening complications despite supportive care. Patients with severely compromised bone marrow reserves at baseline should not receive Xofigo®.
- Sexual Function/Reproduction: Because of the potential effects on spermatogenesis associated with radiation, men who are sexually active should be advised to use condoms. Female partners of reproductive potential should use effective contraception during, and for 6 months after their partner's treatment with Xofigo®. There is a potential risk that radiation from Xofigo® could cause adverse effects on testes.

For more information:

Please consult the Product Monograph available at <http://bayer.ca/files/XOFIGO-PM-EN-10MAR2015-161312.pdf> for important information relating to adverse reactions, drug interactions, and dosing information that has not been discussed in this piece. The Product Monograph is also available by calling 1-800-265-7382.



©XOFIGO is a trademark of Bayer AG, used under license by Bayer Inc.
 ©Bayer and the Bayer Cross are registered trademarks of Bayer AG, used under license by Bayer Inc.
 © 2015, Bayer Inc.

Bayer Inc.
 2920 Matheson Boulevard East
 Mississauga, Ontario L4W 5R6

Member

 L.CA.MKT.05.2015.0769